tiprankstipranks
Ocular Therapeutix (CH:0OT)
:0OT
Switzerland Market
0OT
Ocular Therapeutix
RESEARCH TOOLSreports

Ocular Therapeutix (0OT) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

0OT Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Ocular
Therapeutix
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0OT Stock 12 Month Forecast

Average Price Target

―
Based on 10 Wall Street analysts offering 12 month price targets for Ocular Therapeutix in the last 3 months. The average price target is CHF20.67 with a high forecast of CHF24.85 and a low forecast of CHF14.43. The average price target represents a ― change from the last price of ―.
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
Highest Price TargetCHF24.85Average Price TargetCHF20.67Lowest Price TargetCHF14.43
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on CH:0OT
Biren Amin
Piper Sandler
Piper Sandler
CHF24.85
Buy
―
Reiterated
08/26/26
Analysts Are Bullish on Top Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Ocular Therapeutix (OCUL)
Bank of America Securities Analyst forecast on CH:0OT
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
CHF21.65
Buy
―
Reiterated
08/20/26
Axpaxli’s Differentiated Long-Acting Profile and Multibillion-Dollar Potential Support Buy Rating and Unchanged $27 Price Target
Clear Street Analyst forecast on CH:0OT
William Maughan
Clear Street
Clear Street
CHF22.45
Buy
―
Reiterated
08/18/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (NASDAQ: AMGN), Quince Therapeutics (NASDAQ: QNCX) and Ocular Therapeutix (NASDAQ: OCUL)
Needham Analyst forecast on CH:0OT
Serge Belanger
Needham
Needham
CHF14.43
Buy
―
Reiterated
08/17/26
Ocular Therapeutix Maintained at Buy as Axpaxli’s Superior Durability Supports Unchanged $18 Price Target
William Blair Analyst forecast on CH:0OT
Lachlan Hanbury Brown
William Blair
William Blair
―
Buy
―
Reiterated
08/17/26
Ocular Therapeutix Earns Buy Rating as Axpaxli Differentiation and LUGANO TKI Data Bolster Confidence in Lead Asset
H.C. Wainwright Analyst forecast on CH:0OT
Yi Chen
H.C. Wainwright
H.C. Wainwright
CHF20.04
Buy
―
Reiterated
08/04/26
Analysts Are Bullish on Top Healthcare Stocks: Ocular Therapeutix (OCUL), Keros Therapeutics (KROS)
TD Cowen Analyst forecast on CH:0OT
Tara Bancroft
TD Cowen
TD Cowen
CHF16.04
Buy
―
Reiterated
08/03/26
Ocular Therapeutix Earns Buy Rating on Reduced Regulatory Risk and Strong Axpaxli NDA Visibility
RBC Capital Analyst forecast on CH:0OT
Lisa Walter
RBC Capital
RBC Capital
CHF24.05
Buy
―
Reiterated
08/03/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Ocular Therapeutix (NASDAQ: OCUL) and Arcus Biosciences (NYSE: RCUS)
Chardan Capital Analyst forecast on CH:0OT
Daniil Gataulin
Chardan Capital
Chardan Capital
CHF16.84→CHF18.44
Buy
―
Reiterated
06/25/26
Analysts Conflicted on These Healthcare Names: Repligen (NASDAQ: RGEN), Exelixis (NASDAQ: EXEL) and Ocular Therapeutix (NASDAQ: OCUL)
Robert W. Baird Analyst forecast on CH:0OT
Colleen M. Kusy
Robert W. Baird
Robert W. Baird
CHF19.24→CHF24.05
Buy
―
Reiterated
06/18/26
Ocular Therapeutix price target raised to $30 from $24 at BairdOcular Therapeutix price target raised to $30 from $24 at Baird
Citizens JMP Analyst forecast on CH:0OT
Jonathan Wolleben
Citizens JMP
Citizens JMP
―
Buy
―
Reiterated
02/17/26
Ocular Therapeutix selloff brings attractive entry point, says CitizensOcular Therapeutix selloff brings attractive entry point, says Citizens
Jefferies Analyst forecast on CH:0OT
Clara Dong
Jefferies
Jefferies
CHF22.45
Buy
―
Reiterated
02/17/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (Other OTC: SNYNF) and Ocular Therapeutix (NASDAQ: OCUL)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on CH:0OT
Biren Amin
Piper Sandler
Piper Sandler
CHF24.85
Buy
―
Reiterated
08/26/26
Analysts Are Bullish on Top Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Ocular Therapeutix (OCUL)
Bank of America Securities Analyst forecast on CH:0OT
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
CHF21.65
Buy
―
Reiterated
08/20/26
Axpaxli’s Differentiated Long-Acting Profile and Multibillion-Dollar Potential Support Buy Rating and Unchanged $27 Price Target
Clear Street Analyst forecast on CH:0OT
William Maughan
Clear Street
Clear Street
CHF22.45
Buy
―
Reiterated
08/18/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (NASDAQ: AMGN), Quince Therapeutics (NASDAQ: QNCX) and Ocular Therapeutix (NASDAQ: OCUL)
Needham Analyst forecast on CH:0OT
Serge Belanger
Needham
Needham
CHF14.43
Buy
―
Reiterated
08/17/26
Ocular Therapeutix Maintained at Buy as Axpaxli’s Superior Durability Supports Unchanged $18 Price Target
William Blair Analyst forecast on CH:0OT
Lachlan Hanbury Brown
William Blair
William Blair
―
Buy
―
Reiterated
08/17/26
Ocular Therapeutix Earns Buy Rating as Axpaxli Differentiation and LUGANO TKI Data Bolster Confidence in Lead Asset
H.C. Wainwright Analyst forecast on CH:0OT
Yi Chen
H.C. Wainwright
H.C. Wainwright
CHF20.04
Buy
―
Reiterated
08/04/26
Analysts Are Bullish on Top Healthcare Stocks: Ocular Therapeutix (OCUL), Keros Therapeutics (KROS)
TD Cowen Analyst forecast on CH:0OT
Tara Bancroft
TD Cowen
TD Cowen
CHF16.04
Buy
―
Reiterated
08/03/26
Ocular Therapeutix Earns Buy Rating on Reduced Regulatory Risk and Strong Axpaxli NDA Visibility
RBC Capital Analyst forecast on CH:0OT
Lisa Walter
RBC Capital
RBC Capital
CHF24.05
Buy
―
Reiterated
08/03/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Ocular Therapeutix (NASDAQ: OCUL) and Arcus Biosciences (NYSE: RCUS)
Chardan Capital Analyst forecast on CH:0OT
Daniil Gataulin
Chardan Capital
Chardan Capital
CHF16.84→CHF18.44
Buy
―
Reiterated
06/25/26
Analysts Conflicted on These Healthcare Names: Repligen (NASDAQ: RGEN), Exelixis (NASDAQ: EXEL) and Ocular Therapeutix (NASDAQ: OCUL)
Robert W. Baird Analyst forecast on CH:0OT
Colleen M. Kusy
Robert W. Baird
Robert W. Baird
CHF19.24→CHF24.05
Buy
―
Reiterated
06/18/26
Ocular Therapeutix price target raised to $30 from $24 at BairdOcular Therapeutix price target raised to $30 from $24 at Baird
Citizens JMP Analyst forecast on CH:0OT
Jonathan Wolleben
Citizens JMP
Citizens JMP
―
Buy
―
Reiterated
02/17/26
Ocular Therapeutix selloff brings attractive entry point, says CitizensOcular Therapeutix selloff brings attractive entry point, says Citizens
Jefferies Analyst forecast on CH:0OT
Clara Dong
Jefferies
Jefferies
CHF22.45
Buy
―
Reiterated
02/17/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (Other OTC: SNYNF) and Ocular Therapeutix (NASDAQ: OCUL)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ocular Therapeutix

3 Months
Jonathan WollebenCitizens JMP
Success Rate
17/27 ratings generated profit
63%
Average Return
+15.94%
Copying Jonathan Wolleben's trades and holding each position for 3 Months would result in 62.96% of your transactions generating a profit, with an average return of +15.94% per trade.
1 Year
Yi ChenH.C. Wainwright
Success Rate
18/23 ratings generated profit
78%
Average Return
+19.58%
Copying Yi Chen's trades and holding each position for 1 Year would result in 78.26% of your transactions generating a profit, with an average return of +19.58% per trade.
2 Years
Jonathan WollebenCitizens JMP
Success Rate
24/27 ratings generated profit
89%
Average Return
+102.67%
Copying Jonathan Wolleben's trades and holding each position for 2 Years would result in 88.89% of your transactions generating a profit, with an average return of +102.67% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0OT Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
24
14
16
14
19
Buy
6
4
4
2
3
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
30
18
20
16
22
In the current month, 0OT has received 22 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 0OT average Analyst price target in the past 3 months is 20.67.
Each month's total comprises the sum of three months' worth of ratings.

0OT Financial Forecast

0OT Earnings Forecast

Next quarter’s earnings estimate for 0OT is -CHF0.30 with a range of -CHF0.31 to -CHF0.26. The previous quarter’s EPS was -CHF0.28. 0OT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0OT has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0OT is -CHF0.30 with a range of -CHF0.31 to -CHF0.26. The previous quarter’s EPS was -CHF0.28. 0OT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0OT has Performed in-line its overall industry.

0OT Sales Forecast

Next quarter’s sales forecast for 0OT is CHF11.62M with a range of CHF10.87M to CHF12.98M. The previous quarter’s sales results were CHF10.93M. 0OT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0OT has Performed in-line its overall industry.
Next quarter’s sales forecast for 0OT is CHF11.62M with a range of CHF10.87M to CHF12.98M. The previous quarter’s sales results were CHF10.93M. 0OT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0OT has Performed in-line its overall industry.

0OT Stock Forecast FAQ

What is CH:0OT’s average 12-month price target, according to analysts?
Based on analyst ratings, Ocular Therapeutix’s 12-month average price target is 20.67.
    What is CH:0OT’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:0OT, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Ocular Therapeutix a Buy, Sell or Hold?
        Ocular Therapeutix has a consensus rating of Strong Buy, which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
          What is Ocular Therapeutix’s share price target?
          The average share price target for Ocular Therapeutix is 20.67. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF24.85 ,and the lowest forecast is CHF14.43. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Ocular Therapeutix?
            Ocular Therapeutix’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
              How can I buy shares of Ocular Therapeutix?
              To buy shares of CH:0OT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.